Synergistic antiviral activity of acyclovir and interferon on human cytomegalovirus.
The efficacy of human alpha interferon (IFN-alpha) combined with 9-(2'-hydroxyethoxymethyl)guanine (acyclovir; ACV), (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-beta-D-arabinofuranosyladenine, or 1-beta-D-arabinofuranosylcytosine on the inhibition of human cytomegalovirus (HCMV) replication in human embryonic lung cells was analyzed by plaque reduction assays. IFN-alpha combined with 9-beta-D-arabinofuranosyladenine or 1-beta-D-arabinofuranosylcytosine produced an additive antiviral activity with respect to HCMV plaque formation. IFN-alpha combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine also exhibited additive antiviral activity. However, IFN-alpha combined with ACV at concentrations higher than 10 microM consistently yielded synergistic activity in HCMV plaque reduction assays. Kinetic analyses of HCMV replication demonstrated that approximately a 1,000-fold reduction can be attained through the synergistic interaction between ACV (200 microM) and IFN-alpha (42 IU/ml). These data suggest that combined ACV and IFN-alpha treatment may be useful against HCMV infection.
D000212:Acyclovir / Q000494:pharmacology*; D000998:Antiviral Agents; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives / Q000494:pharmacology; D002478:Cells, Cultured; D003561:Cytarabine / Q000494:pharmacology; D003587:Cytomegalovirus / Q000187:drug effects*; D004357:Drug Synergism; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007700:Kinetics; D014740:Vidarabine / Q000494:pharmacology; D010948:Viral Plaque Assay
D000998:Antiviral Agents; D007370:Interferon Type I; D003561:Cytarabine; C020235:brivudine; D014740:Vidarabine; D001973:Bromodeoxyuridine; D000212:Acyclovir